Our understanding on human neurodegenerative disease was previously limited to clinical data and inferences about the underlying pathology based on histopathological examination. Animal models and in vitro experiments have provided evidence for a cell-autonomous and a non-cell-autonomous mechanism for the accumulation of neuropathology. Combining modern neuroimaging tools to identify distinct neural networks (connectomics) with target-specific positron emission tomography (PET) tracers is an emerging and vibrant field of research with the potential to examine the contributions of cell-autonomous and non-cell-autonomous mechanisms to the spread of pathology. The evidence provided here suggests that both cell-autonomous and non-cell-autonomous processes relate to the observed in vivo characteristics of protein pathology and neurodegeneration across the disease spectrum. We propose a synergistic model of cell-autonomous and non-cell-autonomous accounts that integrates the most critical factors (i.e., protein strain, susceptible cell feature and connectome) contributing to the development of neuronal dysfunction and in turn produces the observed clinical phenotypes. We believe that a timely and longitudinal pursuit of such research programs will greatly advance our understanding of the complex mechanisms driving human neurodegenerative diseases.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
Tax calculation will be finalised during checkout.
Bischof GN, Endepols H, van Eimeren T, Drzezga A. Tau-imaging in neurodegeneration. Methods. 2017;130:114–23.
Hammes J, Bischof GN, Drzezga A. Molecular imaging in early diagnosis, differential diagnosis and follow-up of patients with neurodegenerative diseases. Clin Transl Imaging. 2017;5:465–71.
Teipel S, Drzezga A, Grothe MJ, Barthel H, Chételat G, Schuff N, et al. Multimodal imaging in Alzheimer’s disease: validity and usefulness for early detection. Lancet Neurol. 2015;14:1037–53.
Strafella AP, Bohnen NI, Perlmutter JS, Eidelberg D, Pavese N, Van Eimeren T, et al. Molecular imaging to track Parkinson’s disease and atypical parkinsonisms: new imaging frontiers. Mov Disord. 2017;32:181–92.
Barthel H, Sabri O. Clinical use and utility of amyloid imaging. J Nucl Med. 2017;58:1711–7.
Saint-Aubert L, Lemoine L, Chiotis K, Leuzy A, Rodriguez-Vieitez E, Nordberg A. Tau PET imaging: present and future directions. Mol Neurodegen [Internet] 2017 [cited 2017 Mar 31];12. Available from: http://molecularneurodegeneration.biomedcentral.com/articles/10.1186/s13024-017-0162-3
Passamonti L, Vázquez Rodríguez P, Hong YT, Allinson KSJ, Williamson D, Borchert RJ, et al. 18F-AV-1451 positron emission tomography in Alzheimer’s disease and progressive supranuclear palsy. Brain. 2017.
Boche D, Gerhard A, Rodriguez-Vieitez E. Prospects and challenges of imaging neuroinflammation beyond TSPO in Alzheimer’s disease. Eur. J. Nucl. Med. Mol. Imaging. 2019 (In press).
Grothe M, Heinsen H, Teipel SJ. Atrophy of the cholinergic basal forebrain over the adult age range and in early stages of Alzheimer’s disease. Biol Psychiatry. 2012;71:805–13.
Grothe MJ, Ewers M, Krause B, Heinsen H, Teipel SJ, Alzheimer’s Disease Neuroimaging Initiative. Basal forebrain atrophy and cortical amyloid deposition in nondemented elderly subjects. Alzheimers Dement. 2014;10:S344–53.
Richter N, Beckers N, Onur OA, Dietlein M, Tittgemeyer M, Kracht L, et al. Effect of cholinergic treatment depends on cholinergic integrity in early Alzheimer’s disease. Brain. 2018;141:903–15.
Sabri O, Meyer PM, Gräf S, Hesse S, Wilke S, Becker G-A, et al. Cognitive correlates of α4β2 nicotinic acetylcholine receptors in mild Alzheimer’s dementia. Brain. 2018;141:1840–54.
Kocagoncu E, Quinn A, Firouzian A, Cooper E, Greve A, Gunn R, et al. Tau pathology in early Alzheimer’s disease disrupts selective neurophysiological networks dynamics. bioRxiv. 2019:524355.
Hoenig MC, Bischof GN, Seemiller J, Hammes J, Kukolja J, Onur ÖA, et al. Networks of tau distribution in Alzheimer’s disease. Brain. 2018.
Grothe MJ, Sepulcre J, Gonzalez-Escamilla G, Jelistratova I, Schöll M, Hansson O, et al. Molecular properties underlying regional vulnerability to Alzheimer’s disease pathology. Brain. 2018;141:2755–71.
Grothe MJ, Teipel SJ, Alzheimer’s Disease Neuroimaging Initiative. Spatial patterns of atrophy, hypometabolism, and amyloid deposition in Alzheimer’s disease correspond to dissociable functional brain networks. Hum Brain Mapp. 2016;37:35–53.
Drzezga A. The network degeneration hypothesis: spread of neurodegenerative patterns along neuronal brain networks. J Nucl Med. 2018;59:1645–8.
Chételat G, Villemagne VL, Bourgeat P, Pike KE, Jones G, Ames D, et al. Relationship between atrophy and beta-amyloid deposition in Alzheimer disease. Ann Neurol. 2010;67:317–24.
Myers N, Pasquini L, Göttler J, Grimmer T, Koch K, Ortner M, et al. Within-patient correspondence of amyloid-β and intrinsic network connectivity in Alzheimer’s disease. Brain. 2014;137:2052–64.
Drzezga A, Becker JA, Van Dijk KRA, Sreenivasan A, Talukdar T, Sullivan C, et al. Neuronal dysfunction and disconnection of cortical hubs in non-demented subjects with elevated amyloid burden. Brain. 2011;134:1635–46.
Koch K, Myers NE, Göttler J, Pasquini L, Grimmer T, Förster S, et al. Disrupted intrinsic networks link amyloid-β pathology and impaired cognition in prodromal Alzheimer’s disease. Cereb Cortex. 2015;25:4678–88.
Jones DT, Graff-Radford J, Lowe VJ, Wiste HJ, Gunter JL, Senjem ML, et al. Tau, amyloid, and cascading network failure across the Alzheimer’s disease spectrum. Cortex. 2017;97:143–59.
Cope TE, Rittman T, Borchert RJ, Jones PS, Vatansever D, Allinson K, et al. Tau burden and the functional connectome in Alzheimer’s disease and progressive supranuclear palsy. Brain. 2018;141:550–67.
Franzmeier N, Rubinski A, Neitzel J, Kim Y, Damm A, Na DL, et al. Functional connectivity associated with tau levels in ageing, Alzheimer’s, and small vessel disease. Brain. 2019.
Neitzel J, Franzmeier N, Rubinski A, Ewers M. Left frontal connectivity attenuates the adverse effect of entorhinal tau pathology on memory. Neurology. 2019; in press.
Rabin JS, Perea RD, Buckley RF, Neal TE, Buckner RL, Johnson KA, et al. Global White matter diffusion characteristics predict longitudinal cognitive change independently of amyloid status in clinically Normal older adults. Cereb Cortex. 2019;29:1251–62.
Strain JF, Smith RX, Beaumont H, Roe CM, Gordon BA, Mishra S, et al. Loss of white matter integrity reflects tau accumulation in Alzheimer disease defined regions. Neurology. 2018;91:e313–8.
Jacobs HIL, Hedden T, Schultz AP, Sepulcre J, Perea RD, Amariglio RE, et al. Structural tract alterations predict downstream tau accumulation in amyloid-positive older individuals. Nat Neurosci. 2018;21:424–31.
Zempel H, Mandelkow E. Lost after translation: missorting of tau protein and consequences for Alzheimer disease. Trends Neurosci. 2014;37:721–32.
Hammes J, Theis H, Giehl K, Hoenig MC, Greuel A, Tittgemeyer M, et al. Dopamine metabolism of the nucleus accumbens and fronto-striatal connectivity modulate impulse control. Brain. 2019;142:733–43.
Strafella AP. Mesolimbic dopamine and anterior cingulate cortex connectivity changes lead to impulsive behaviour in Parkinson’s disease. Brain. 2019;142:496–8.
Gargouri F, Gallea C, Mongin M, Pyatigorskaya N, Valabregue R, Ewenczyk C, et al. Multimodal magnetic resonance imaging investigation of basal forebrain damage and cognitive deficits in Parkinson’s disease. Mov Disord. 2019;34:516–25.
Tahmasian M, Eickhoff SB, Giehl K, Schwartz F, Herz DM, Drzezga A, et al. Resting-state functional reorganization in Parkinson’s disease: an activation likelihood estimation meta-analysis. Cortex. 2017;92:119–38.
Lang S, Hanganu A, Gan LS, Kibreab M, Auclair-Ouellet N, Alrazi T, et al. Network basis of the dysexecutive and posterior cortical cognitive profiles in Parkinson’s disease. Mov Disord. 2019.
Tessitore A, De Micco R, Giordano A, di Nardo F, Caiazzo G, Siciliano M, et al. Intrinsic brain connectivity predicts impulse control disorders in patients with Parkinson’s disease. Mov Disord. 2017;32:1710–9.
Horn A, Reich M, Vorwerk J, Li N, Wenzel G, Fang Q, et al. Connectivity predicts deep brain stimulation outcome in Parkinson disease. Ann Neurol. 2017;82:67–78.
Sepulcre J, Grothe MJ, d’Oleire Uquillas F, Ortiz-Terán L, Diez I, Yang H-S, et al. Neurogenetic contributions to amyloid beta and tau spreading in the human cortex. Nat Med. 2018;24:1910–8.
Rittman T, Rubinov M, Vértes PE, Patel AX, Ginestet CE, Ghosh BCP, et al. Regional expression of the MAPT gene is associated with loss of hubs in brain networks and cognitive impairment in Parkinson disease and progressive supranuclear palsy. Neurobiol Aging. 2016;48:153–60.
Freeze B, Acosta D, Pandya S, Zhao Y, Raj A. Regional expression of genes mediating trans-synaptic alpha-synuclein transfer predicts regional atrophy in Parkinson disease. Neuroimage Clin. 2018;18:456–66.
Zeighami Y, Ulla M, Iturria-Medina Y, Dadar M, Zhang Y, KM-H L, et al. Network structure of brain atrophy in de novo Parkinson’s disease. Elife. 2015;4.
Yang H-S, Yu L, White CC, Chibnik LB, Chhatwal JP, Sperling RA, et al. Evaluation of TDP-43 proteinopathy and hippocampal sclerosis in relation to APOE ε4 haplotype status: a community-based cohort study. Lancet Neurol. 2018;17:773–81.
van Eimeren T, Antonini A, Berg D, Bohnen N, Ceravolo R, Drzezga A, et al. Neuroimaging biomarkers for clinical trials in atypical parkinsonian disorders: proposal for a neuroimaging biomarker utility system. Alzheimers Dement (Amst). 2019;11:301–9.
Faculty of the Multimodal Imaging in Neurodegeneration Cologne (MINC) symposium
The Molecular Imaging of Neurodegeneration Cologne (MINC) Symposium was partly funded by the Deutsche Forschungsgemeinschaft (DFG) awarded to Dr. Thilo van Eimeren (EI 892/5–1). The Deutsche Forschungsgemeinschaft (DFG) also awarded funding to Dr. Alexander Drzezga (DR 442/91).
Conflict of interest
The authors declare no conflict of interest in relation to this article.
This article does not contain any studies with human participants performed by any of the authors.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
This article is part of the Topical Collection on Advanced Image Analyses (Radiomics and Artificial Intelligence).
About this article
Cite this article
Bischof, G.N., Ewers, M., Franzmeier, N. et al. Connectomics and molecular imaging in neurodegeneration. Eur J Nucl Med Mol Imaging 46, 2819–2830 (2019). https://doi.org/10.1007/s00259-019-04394-5
- Multimodal Imaging
- Functional Connectivity
- Pathophysiological Spreading
- Selective Vulnerability